12:00 AM
 | 
Jan 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

RM-493: Phase II started

Rhythm began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 1 mg subcutaneous RM-493 given daily in 70 patients for 3 months. Rhythm has...

Read the full 105 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >